We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Orchard Therapeutics Launched

Orchard Therapeutics Launched

Orchard Therapeutics Launched

Orchard Therapeutics Launched

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Orchard Therapeutics Launched"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

UCL Business, the technology transfer company of UCL, and venture capital firm F-Prime Capital Partners have launched Orchard Therapeutics, a biotechnology company specialising in gene therapies for life threatening rare childhood diseases.

Orchard Therapeutics has secured £21 million investment led by F-Prime to support the development of gene therapy treatments for a range of diseases.

As part of its launch, Orchard announced formal partnerships with UCL, Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), University of California Los Angeles (UCLA), The University of Manchester, Boston Children’s Hospital for the development of these transformative gene therapies.

Orchard’s lead programme is for the treatment of the rare and fatal disorder called severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID), sometimes referred to as “bubble baby” syndrome in the press. Children with the disorder must be protected from any infections due to their highly fragile immune system.

In a first-in-man clinical study, global leaders in the field at UCL/GOSH and UCLA have shown significant immune reconstitution and 100% survival in 32 patients treated, as of March 2016.

Orchard’s financing has been led by F-Prime Capital, with support from UCLB and additional participation from the UCL Technology Fund.

Cengiz Tarhan, Managing Director of UCLB, said:

“We are very excited to see UCL’s breakthrough treatments move forward in a commercial environment in a way that will benefit patients globally. The formation of Orchard represents the culmination of decades of research at UCL and its partners and we are delighted to be able to work with F-Prime Capital to launch Orchard.”